Combined continuous hormone therapy (HT) probably leads to higher coronary events (MI or cardiac death) compared with placebo (moderate certainty).
Combined continuous hormone therapy (HT) probably leads to higher stroke compared with placebo (moderate certainty).
Combined continuous hormone therapy (HT) probably leads to higher venous thromboembolism (DVT or PE) compared with placebo (moderate certainty).
Combined continuous hormone therapy (HT) probably leads to higher breast cancer compared with placebo (moderate certainty).
Combined continuous hormone therapy (HT) probably leads to higher death from lung cancer compared with placebo (moderate certainty).
Combined continuous hormone therapy (HT) probably leads to higher gallbladder disease compared with placebo (moderate certainty).
Combined continuous hormone therapy (HT) probably leads to lower all clinical fractures compared with placebo (moderate certainty).
It is very uncertain whether oestrogen in combination with progestogen (sequential or continuous) changes withdrawal due to adverse events over 2 to 4 menstrual cycles1 compared with placebo (very low certainty).
It is very uncertain whether oestrogen in combination with progestogen (sequential or continuous) changes specific adverse events over 2 to 4 menstrual cycles1 compared with placebo (very low certainty).